Background & Aims: Pre-clinical studies have shown aspirin to have anti-cancer
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Introduction
Gastric and esophageal cancer are the third and eighth most common cancers worldwide, comprising 6.8% and 3.2% of total cancer incidence, respectively. 1 These cancers have poor prognosis (with 5 year survival rates of gastric cancer of 29% and esophageal cancer of 20%), 2 highlighting the need for additional treatment options.
Aspirin is used as an analgesic at high doses, and as an anti-platelet to prevent cardiovascular disease at low-doses (usually around 75mg). 3 Platelets play an important role in cancer growth and metastasis [4] [5] [6] and aspirin has been shown to prevent experimentally induced metastases in mice. 7 In humans, long term follow-up of randomised controlled trials of aspirin to prevent vascular events, have shown a 50% reduction in cancer-specific death in esophageal and gastric cancer patients on aspirin, 8 and a 60% reduction in the risk of metastases in non-colorectal gastrointestinal cancer patients on aspirin. 9 These protective effects were observed regardless of aspirin dose but were only observed for adenocarcinomas. 8;9 However, as these patients were taking aspirin prior to esophageal or gastric cancer diagnosis it remains unclear whether low-dose aspirin use after cancer diagnosis, a time point more relevant for clinical intervention, confers any benefit. Furthermore, a more recent meta-analysis by the United States Preventive Services Task Force concluded that the effect of aspirin on cancer mortality was not clearly established. 10 Unfortunately, there have not been any epidemiological studies that have investigated the association between low-dose aspirin use after diagnosis of gastric or esophageal cancer and cancer-specific mortality. Three independent studies [11] [12] [13] have reported marked protective effects of aspirin on all-cause mortality in gastric and esophageal cancer patients, but these associations could reflect non-cancer mortality. Furthermore, in two studies these associations were restricted to subgroups of esophageal cancer patients 12 and esophageal squamous cell carcinoma patients, 13 and in the third study, 11 the associations were attenuated when methods to reduce immortal time bias were employed. Further evidence on the impact of low-dose aspirin use in patients with esophageal or gastric cancer is required to inform the decision to start trials, and inform the conduct of ongoing trials. 14 Using two independent population-based datasets, we investigated the association between low-dose aspirin use and cancer-specific mortality in patients with esophageal or gastric cancer.
Materials & methods
Data sources
England: The English data were based upon the UK Clinical Practice Research Datalink (CPRD), linked with the Office for National Statistics (ONS) and National Cancer Data Repository (NCDR). The NCDR contains data on all patients identified in all English cancer registries, including date and site of primary cancer diagnosis, tumor prognostic features (e.g. stage, grade, morphology) and treatment data. The CPRD is the largest computerized database of its kind in the world. CPRD encompasses approximately 6% of the UK population and is broadly representative in terms of age, sex, ethnicity and body mass index (BMI). 15 The CPRD contains information including patients' diagnoses, demographics, medication prescriptions and comorbidities. The ONS death data for the UK contains information on the causes and dates of death. Linkages of the databases were conducted using the NHS number, date of birth, gender and postcode of each patient. As linkage involved the English NCDR, only patients registered in English GP practices were included in this study.
Ethical approval for research using CPRD data has been obtained from a multicentre research ethics committee. The study protocol was approved by The Independent Information System. A quantity of 28 tablets was assumed for the less than 2% of prescriptions for which quantity was assumed incorrect (if less than seven or greater than 365), as this is the most common number of tablets in a prescription. One tablet of low-dose aspirin daily was assumed to be taken daily, as this has been designated to be the defined daily dose (DDD), by the World Health Organisation classification. 16 High dose aspirin comprised less than 2% of total aspirin prescriptions, during the exposure period in England and Scotland, and was ignored in all analyses.
Confounders
Data on histology (including esophageal adenocarcinoma and squamous cell carcinoma), grade and treatment (radiotherapy, chemotherapy or surgery) within six months of diagnosis were retrieved from cancer registries in England (from NCDR) and the Scottish Cancer Registry. The following comorbidities were identified: acute myocardial infarction, congestive heart disease, peripheral vascular disease, cerebrovascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes and renal disease. In England these comorbidities were identified from GP records before cancer diagnosis (based upon an average of 7.7 years of available records using a previously developed Read code list 17 ). In Scotland these comorbidities were identified from hospital inpatient and outpatient clinic data available from 1999 (using a previously developed ICD code list 18 ). Statin use was determined from medication data as described above. Deprivation level was determined from postcode of residence in England using the English Index of Multiple Deprivation, and in Scotland based upon postcode of residence using the 2009 Scottish Index of Multiple Deprivation. 19 Smoking status (categorised as current, ex or never) and BMI were available from GP diagnosis codes prior to cancer diagnosis within the CPRD cohort; records older than 10 years were discarded.
Statistical analysis
Time-varying Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CI) for cancer-specific mortality comparing aspirin users to non-users in esophageal and gastric cancer sites. In the main analysis lowdose aspirin use from the date of diagnosis was considered a time varying covariate 20 with patients classified as non-users until 6 months after their first prescription at which point they became users until the end of follow-up. Using such a lag is recommended, 21 as low-dose aspirin is unlikely to have an immediate effect on cancer progression. A diagram illustrating this design is shown in Supplementary Figure 1 .
The main model included the following variables: sex, age, year of diagnosis, deprivation (defined above, in fifths), cancer treatment within 6 months (using separate variables for radiotherapy, chemotherapy and surgery), comorbidities prior to diagnosis (using separate variables for acute myocardial infarction, congestive heart disease, peripheral vascular disease, cerebrovascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes and renal disease) and statin and aspirin use (as time varying covariates, as defined above).
Exposure-response analyses for duration of aspirin use were undertaken using a timevarying covariate with patients deemed non-users until 6 months after their first prescription, a short term user between 6 months after their first prescription and 6 months after their 365 th tablet and a long term user after this time. Similar analyses were also conducted for different total amounts of low-dose aspirin use (182, 365, 548 and 730 tablets). Tests for trend were calculated, within the regression models using Wald tests, based upon the estimated HR per category increase of aspirin use.
Separate analyses were conducted within esophageal cancer cases by histology (adenocarcinoma and squamous cell carcinoma) and for adenocarcinoma in gastric cancer patients. Summary HRs and standard errors from England and Scotland were combined using fixed effects models to calculate pooled HRs. 22 The probabilities of survival at 1 year after the start of follow-up was estimated in aspirin users and nonusers, based upon cancer-specific mortality in Kaplan-Meier curves plotted using the Simon and Makuch method to account for aspirin as a time varying covariate. 23 All analyses were conducted using STATA 14 (StataCorp, College Station, TX, USA) statistical analysis software.
Sensitivity analyses were conducted with a lag of zero years (in which the accrual of person years at risk began at diagnosis, and all deaths after diagnosis were included), a lag of 3 months (in which the accrual of person years at risk began at 3 months, and deaths in the first 3 months were excluded) and a lag of 1 year (in which the accrual of person years at risk began from 1 year after diagnosis, and deaths in the first year after diagnosis were excluded), see Supplementary Figure 1 for an illustration. Two simplified analyses, which control for immortal time bias without using time-varying covariates, 20 were conducted. First, aspirin exposure was based on any use in the year prior to diagnosis (in which the accrual of person years at risk began at diagnosis, and all deaths after diagnosis were included). Second, aspirin exposure was based on any use during the six months after diagnosis and the accrual of person years at risk began six months after diagnosis. Additional analyses were conducted comparing aspirin users with non-users after restricting each cohort to patients who did not use aspirin in the year prior to cancer diagnosis, and conversely those who were aspirin users prior to cancer diagnosis. Further analyses were also conducted comparing aspirin users with non-users after diagnosis adjusting for aspirin use in the year prior to diagnosis and comparing aspirin users with non-users after diagnosis stratifying by statin use during that time period. A separate analysis was also conducted additionally adjusting for tumor grade as well as an analysis restricted to patients treated with surgery, a more homogeneous cohort of lower stage patients. Analyses were repeated for allcause mortality outcomes.
Further adjustments were possible in the English data only, in which cancer stage, smoking and BMI were available. We performed additional sensitivity analysis adjusting for tumor prognostic features (stage, grade) and patient lifestyle factors (smoking, alcohol consumption, obesity) using complete-case and multiple imputation with chained equations (MICE). The MICE imputation used ordered logit models with age, deprivation, death indicator and the baseline hazard function as covariates. 24 Briefly, MICE is a simulation-based approach for handling missing data which leads to valid statistical inferences under certain circumstances. 25 For comparison with a previous study, 12;26 a start/stop time-varying covariate analysis was conducted, basically investigating current aspirin use, in which patients became aspirin users upon the date of each aspirin prescription, and remained aspirin users for the duration of the prescription at which point they became aspirin non-users. These analyses were conducted with no lag, a 6 month lag (accrual of person years at risk starts at 6 months after diagnosis and the dates of aspirin prescriptions were moved forward 6 months) and a 1 year lag (accrual of person years at risk starts at 1 years and the date of aspirin prescriptions were moved forward 1 year) as described above and were adjusted for the confounders mentioned previously. Supplementary Figure 1 contains diagrams illustrating these designs.
A separate sensitivity analysis was conducted to investigate the association between cancer-specific mortality and consistent aspirin use. A nested case-control design was used in which cases who died due to esophageal or gastric cancer were matched on age (in 5 year intervals), year of cancer diagnosis (in 1 year intervals), gender and site (esophageal or gastric cancer) to up to five esophageal or gastric cancer risk-set controls who lived at least as long after their cancer diagnosis. The exposure period was from cancer diagnosis until 6 months prior to cancer-specific death in cases and for a period of identical duration from diagnosis in matched controls. Patients who died within 6 months of diagnosis were excluded. The number of aspirin tablets per day in the exposure period was determined and patients with greater than 0.8 (i.e. using over 80% of the time) were considered consistent aspirin users. Conditional logistic regression was then used to calculate odds ratios (ORs), and 95% CIs, for the association between consistent aspirin use and cancer-specific mortality, adjusting for treatment, deprivation, comorbidities and statin use.
Results
Patient cohorts
In the English cohort there were 11,044 gastroesophageal cancer patients. After exclusion criteria were applied, 2,733 esophageal cancer and 2,391 gastric cancer patients remained for analysis (Figure 1 Tables 1 and 2 , respectively. For both esophageal and gastric cancer cohorts, aspirin users, compared with non-users, were more likely to be male, older, have a history of comorbidities and use statins. Aspirin users in the gastric cancer cohort were slightly more likely to have surgery and radiotherapy, but less likely to have chemotherapy and higher grade tumors than non-users. Aspirin users in the esophageal cancer cohort were also more likely to undergo radiotherapy, and less likely to have chemotherapy, however the rates of surgery were similar when compared to non-users.
Association between aspirin use after diagnosis and survival
In esophageal cancer patients, the proportion surviving 1 year from the start of follow-up, based upon cancer-specific mortality, in aspirin users and non-users was 49% and 46% in Scotland and 48% and 50% in England, respectively. Similarly in gastric cancer patients, the proportion surviving 1 year in aspirin users versus nonusers was 59% and 55% in Scotland and 58% versus 57% in England, respectively. Table 3 . Table 4 shows sensitivity analyses. In the majority of sensitivity analyses, the conclusions were little altered. In unlagged analysis for esophageal and gastric cancer, there was a slight reduction in cancer-specific mortality in aspirin users compared 
Sensitivity analyses
Discussion
In two large independent population-based cohorts of esophageal and gastric cancer patients we did not find any evidence that low-dose aspirin use reduced the risk of cancer-specific or all-cause mortality.
To date there have not been any previous studies investigating the impact of aspirin use on cancer-specific mortality in esophageal or gastric cancer patients. Only one observational study has investigated aspirin after diagnosis and all-cause mortality in 
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However it is possible that their analysis, which was of current aspirin use (using a start/stop time-varying covariate), could have led to reverse causation. Specifically, current aspirin users became aspirin non-users once their prescription was complete, therefore if medications were withdrawn from individuals who become terminally ill (as has been observed at other cancer sites 27 ) then aspirin could artificially appear protective. Consistent with this bias, when we fitted models of current aspirin use (using a start/stop time-varying covariate) we observed similar marked protective effects, which seem implausible, and which were entirely attenuated once a year lag was used. In our main analysis we used a lag and once an individual became an aspirin user they remained an aspirin user, as seen in similar studies, 28;29 which reduces this potential bias.
A study based upon 2392 esophageal cancer patients from Scotland also observed a protective association for all-cause mortality in aspirin users after diagnosis (adjusted HR 0.54 95% CI 0.45, 0.64). 11 However, this protective association was attenuated in additional nested case-control analyses conducted to reduce immortal time bias, (OR 0.75, 95% CI 0.43, 1.31). Finally, a Chinese study of 1598 esophageal cancer patients observed a slight but significant reduction in 5 year mortality in low-dose aspirin users compared with non-users (relative risk 0.81). 13 However this study did not contain any dose response analyses, did not adjust for comorbidities and was conducted in a very specific cancer subset (undergoing resection for esophageal squamous cell carcinoma or gastric cardia adenocarcinoma). Our findings are similar to a recent US study which investigated aspirin use prior to esophageal cancer in 130 esophageal cancer patients, which found no association between medication use and cancer-specific mortality (HR 1.07 95% CI 0.52, 2.21), 30 however their study did not investigate aspirin use after diagnosis and had limited power.
Long term follow-up of randomised controlled trials of aspirin, designed with the primary aim to prevent vascular events, have detected reductions in the risk of death from esophageal and gastric cancer of around 50%, 8 and reductions in the risk of metastases after non-colorectal gastrointestinal cancer diagnosis by around 60%. 9 It is possible to speculate why we did not observe these protective effects: Firstly, the risk of death from cancer will reflect cancer incidence and it is plausible that aspirin could reduce esophageal and gastric cancer incidence but not improve survival. Similarly, as these trials were of aspirin treatment to reduce vascular events they were not specific to cancer patients and therefore all included individuals in the aspirin group were taking aspirin for many years prior to cancer diagnosis. Finally, patients in these trials may have taken aspirin more regularly than patients in a real life setting, 31;32 but it is worth noting that our analyses of consistent aspirin use and long term aspirin use were also null.
At least one trial is ongoing investigating the effect of aspirin (both 100mg and 300mg) on survival in esophageal and gastric cancer patients. 14 This UK trial will provide more definitive evidence of the effect of low-dose aspirin in esophageal and gastric cancer patients, but a final report is not anticipated until 2027. Should further epidemiological studies observe null results in esophageal cancer patients this could inform the decision to conduct further trials and inform the interim analyses of this trial.
Strengths
The main strength of our study was the use of two large independent population-based cohorts, the long term follow-up (of up to 17 years), size (including 8,487 gastroesophageal patients making this larger than all previous studies of aspirin on survival) and the ability to identify cancer-specific mortality which was not possible in previous studies investigating post-diagnostic aspirin use. We utilised high quality data from a number of sources (including English and Scottish cancer registries, and medication and national mortality records). Also, the use of routinely electronically updated databases eliminated the possibility of recall bias, a significant disadvantage of questionnaire-based studies. 33 
Limitations
We cannot exclude the effect of residual confounding from poorly measured or missing factors. In particular, stage was poorly recorded, although this is likely to bias our estimates toward a more protective effect as aspirin is less likely to be prescribed to patients with more advanced cancer (as seen in the Netherlands cohort in which 9% of stage four patients used aspirin compared with 24% of stage one patients). 12 Furthermore, our conclusions were unchanged in complete case and multiple imputation analyses adjusting for stage in the English cohort. We had limited information on smoking and BMI and only from the English cohort. Despite this, adjustments using complete case and imputation for esophageal and gastric cancer did not alter results. Additionally, misclassification of aspirin is possible as aspirin is available over-the-counter. However, a previous CPRD study estimated that 70% to 80% of aspirin use among middle-aged UK residents was prescription based, 34 whilst another showed little evidence of misclassification of aspirin usage by prescription records when compared with patient recall. 35 Also, a previous methodological study demonstrated that that valid treatment effects can be obtained where over-the-counter usage occurs particularly when medication use is around 35% and OTC use is under 30%, as seems likely in our study. 36 However, we cannot rule out the possibility of non-compliance. Furthermore, in other cancer sites, such as colorectal, aspirin has been shown to be protective only in particular molecular subtypes. 
Conclusions
In conclusion, we found there was no significant reduction in mortality in esophageal or gastric cancer patients with low-dose aspirin use. Our findings do not support the conduct of further trials of low-dose aspirin in esophageal or gastric cancer patients. 
